Jim Burns
CEO
Twelve Bio
Twelve Bio develops CRISPR-Cas12a diagnostic technology that enables precise detection and modification of DNA sequences. This technology addresses the need for accurate genetic diagnostics and targeted gene editing to treat genetic disorders and diseases.
Traction –/10105
Copenhagen, Denmark · HQ
- Biotechnology
Updated today
Funding
Raised to date
$50MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many genetic disorders and diseases require precise detection and modification of DNA sequences, but existing methods can be inefficient or lack the required specificity for safe and effective treatment. Current gene editing technologies may also struggle with targeted delivery to the appropriate cells within the body.
Solution
Ensoma is developing _in vivo_ genomic medicines that precisely engineer any cell of the hematopoietic system to cure diseases from within. Their Engenious™ platform combines an off-the-shelf, _in vivo_ delivery system with an advanced gene engineering toolkit. This hematopoietic stem cell (HSC) engineering platform allows for selective and durable modification of cells within the hematopoietic system, offering a one-time therapy approach. The company aims to create a patient experience defined by simplicity, speed, and safety.
Target Audience
The primary target audience includes patients with genetic disorders, autoimmune diseases, and cancers treatable through engineering of the hematopoietic system, as well as the healthcare providers who treat them.
Features
- Engenious™ platform for _in vivo_ delivery of gene editing payloads
- Hematopoietic stem cell (HSC) engineering for targeted cell modification
- Off-the-shelf, one-time treatment approach
- Versatile platform applicable to genetic, immune, and oncological diseases